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Abstract (Word count: 249 words)   1 
Background Preventing PE is a priority after major musculoskeletal surgery.  There is  2 
discrepancy in published data regarding the influence that anticoagulation has on the 3 
incidence of PE following joint arthroplasty.  The American College of Chest Physicians 4 
guidelines recommend administration of oral anticoagulants (warfarin), aiming for an 5 
INR level between two and three.  However, recent studies show aggressive 6 
anticoagulation (INR greater than two) can lead to hematoma formation and increased 7 
risk of subsequent infection.   8 
Questions/purposes We asked whether an INR greater than two is protective against PE.   9 
Patients and Methods We identified 9,112 patients with 10,122 admissions for joint 10 
arthroplasty between 2004 and 2008.  All patients received warfarin for prophylaxis, 11 
aiming for an INR level of two or below.  Of the 10, 122 admissions, we assessed 609 12 
(6%; 609/10122) for PE using CT, VQ scan, or pulmonary angiography.  Of these, 163 13 
patients (1.6%; 163/10122) had a proven PE.   14 
Results  Of these 163 patients, 9% (15/163) had an INR greater than two prior to or on the 15 
day of work-up compared to 8% (35/446) of patients who were negative.  We observed 16 
no difference between the INR values in patients with or without PE.   17 
Conclusions We found no clinically relevant difference in the INR values of patients who 18 
did or did not develop PE.  The risk of bleeding should be weighed against the risk of PE 19 
when determining an appropriate target INR for each patient, as an INR less than two 20 
may reduce the risk of bleeding while still protecting against PE.   21 
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Level of Evidence: Level III Therapeutic study. See Instructions to Authors for a 22 
complete description of levels of evidence.23 
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Introduction 24 
Pulmonary embolism (PE) is a serious and potentially fatal complication that can develop 25 
following total joint arthroplasty (TJA), with an incidence of 1.1 to 1.82% after total knee 26 
arthroplasty (TKA) and 0.51 to 0.9% after total hip arthroplasty (THA) [12,18,19].  27 
Patients undergoing TJA are considered to be at higher risk for PE. Prevention of PE 28 
following orthopaedic procedures continues to be a priority.  For this reason, various 29 
scientific groups have devised guidelines for implementation of anticoagulation 30 
prophylaxis to minimize this complication [10,11].   31 
In 2008 the American College of Chest Physicians (ACCP) issued updated guidelines 32 
regarding postoperative PE prophylaxis in elective hip or knee arthroplasty [10].  These 33 
guidelines endorse the use of low molecular weight heparin (LMWH), fondaparinux, or 34 
Vitamin-K antagonists to achieve an international normalized ratio (INR) between two 35 
and three.  These guidelines, however, make the assumption that deep venous thrombosis 36 
(DVT) and PE should be treated as the same entity and that the former is likely to lead to 37 
the latter. A recently published study discredited this relationship [16].  Further, the 38 
ACCP guidelines do not account for the risk or severity of bleeding complications 39 
associated with anticoagulation.  At an INR of two to three, the incidence of major 40 
bleeding complications ranges from 5.0% to 5.6% after TKA and 0.6% to 1.6% after 41 
THA [8,9,17].  In those same studies, the rate of minor bleeding complications following 42 
TKA and THA reportedly ranges from 21% to 28% and 4.6% to 13.5%, respectively.  43 
With the increased risk of bleeding complications, it is important to understand the 44 
effectiveness of therapeutic anticoagulation in minimizing PE.  We previously 45 
demonstrated the low risk of complications with the use of low-dose warfarin (i.e. aiming 46 
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for an INR less than two) for preventing PE [1].  That study was the basis for 47 
implementing the use of low-dose warfarin (aiming for an INR less than two) in patients 48 
undergoing TJA in 1990.   49 
We therefore asked whether an INR level greater than two, as dictated by the ACCP 50 
guidelines, following TJA is protective against PE.   51 
Patients and Materials 52 
From our institutional database we retrospectively identified 9,112 patients who 53 
underwent TJA between January 2004 and June 2008 and had at least a single 54 
postoperative INR value available.  Those patients who underwent work-up for PE yet 55 
did not have an INR value on the day of or prior to scan were excluded.  During that 56 
same time, we treated 9,973 patients with TJA.  Therefore, 861 patients were excluded 57 
due to lack of complete data, the demographics of these two groups were investigated 58 
(Table 1).  The 9,112 patients had an average age of 64 years (range, 11-103 years) and 59 
had 10,122 admissions for 11,300 procedures (4,727 primary hips, 5,079 primary knees, 60 
803 revision hips, 615 revision knees, and 76 hemiarthroplasties).  Patients were followed 61 
until discharge from the hospital, on average 6.3 days (range: 2-56 days).  Any patients 62 
with symptoms indicative of PE were investigated.  Since this study observational 63 
window ended at discharge, no patients were lost to followup.  No patients were recalled 64 
specifically for this study; all data was obtained from medical records.   65 
The protocol for anticoagulation at our institution throughout the study period consisted 66 
of administration of 1000 IU of intravenous heparin at the time of dislocation of the hip 67 
during hip arthroplasty and prior to inflation of the tourniquet during knee arthroplasty.  68 
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In addition, we placed patients on oral anticoagulation (warfarin), aiming for an INR 69 
level of two or below. Patients continued on the anticoagulation for a period of six weeks.  70 
The institutional guidelines are modeled after the recommendations from the AAOS [11] 71 
for prevention of PE after TJA.  These guidelines were developed without regard for the 72 
prevention of DVT.  This conflicts with the recommendations made by the ACCP [10], 73 
whose means of PE prevention include prophylaxis against DVT.  There were variations 74 
based on the risk profile of patients for PE and bleeding.  We gave patients at higher risk 75 
of PE low molecular weight heparin in addition to oral anticoagulation until their INR 76 
level reached therapeutic levels.  We considered patients at high risk for PE as those with 77 
previous PE, polycythemia vera, and those in a hypercoagulable state.  On the other hand, 78 
we gave patients at high risk of bleeding aspirin for anticoagulation.  We considered 79 
patients at high risk for bleeding as those with recent cranio-spinal surgery, active gastric 80 
ulcer, and hemophilia.  Prophylaxis with warfarin involved administration of the drug on 81 
the operative day.  We monitored the INR daily while the patient was in the hospital, and 82 
dosed warfarin according to their INR level.  The mean preoperative INR for the entire 83 
cohort of 10,122 admissions was 1.09.  The median daily postoperative values for INR 84 
were 1.13 (range, 0.67-3.04) on postoperative day (POD) zero, 1.24 (range, 0.6-5.8) on 85 
POD one, 1.39 (range, 0.4-7.0) on POD two, 1.32 (range, 0.7-5.3) on POD three, 1.33 86 
(range, 0.9-5.2) on POD four, and 1.41 (range, 0.8-4.3) on POD five (Fig. 1).  The 87 
proportion of patients with an INR greater than two was 0.7 %, 0.2%, 6.4%, 3.1%, 4.5%, 88 
and 8.6% for the POD zero through five, respectively (Fig. 2).  We plotted the percentage 89 
of patients who had an INR greater than two in the PE positive and PE negative groups 90 
against the day of scan, including the five days before and after the scan.  The work-up 91 
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for PE at our institution followed a standard protocol as well.  This protocol underwent 92 
some modification over time.  In general, we first administered oxygen to patients with 93 
hypoxia and monitored them very closely (Appendix).  If within five to ten minutes of 94 
oxygen therapy hypoxia was not resolved, we imaged these patients for PE, which 95 
included multi-detector computed tomography (MDCT), VQ scan and, in rare cases, 96 
pulmonary angiography.  We evaluated patients with other signs suggestive of PE, such 97 
as tachycardia, tachypnea, dyspnea, and so on, thoroughly and, based on the judgment of 98 
the evaluating internist, subjected them for PE work-up.   99 
From among the 10,122 admissions, 600 patients (609 admissions; 6.0 %) were scanned 100 
for PE.  This subset had an average age of 69 years (range, 24-96 years) and consisted of 101 
424 (73.5%) women.  These patients had 710 arthroplasty procedures (194 primary hips, 102 
428 primary knees, 38 revision hip, 42 revision knee, and eight hemiarthroplasties) in 621 103 
admissions.  Following work-up for PE, 163 admissions (163/10,122; 1.6%) were 104 
positive for PE and included in the positive PE subgroup.  Among the 609 admissions 105 
that received work-up for PE, the majority (41.2%; 251/609) were scanned on POD 2 106 
(Fig. 1).  We assessed their daily INR values to identify any variations in their INR 107 
relative to the remaining patients who were negative for PE and the entire arthroplasty 108 
cohort.  We utilized the Charlson comorbidity index [3], as modified by Deyo et al. [5], 109 
to assess comorbidities.  This index is adjusted for age.  Variables describing differences 110 
between PE positive and PE negative patients are reported (Table 2).  Furthermore, the 111 
same variables are reported for patients with a post-operative INR greater than two versus 112 
INR less than two (Table 3).   113 
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To analyze the anticoagulation (INR) levels and confounding variables of the three 114 
cohorts we utilized a series of statistical tests.  First, the data was tested for normality 115 
using the Kolmogorov-Smirnov test.  Normal continuous data was assessed using the 116 
Student’s t-test, and confidence intervals provided clinical significance of variations.  117 
Non-normal continuous data was assessed with the Mann-Whitney test, and twenty-fifth 118 
and seventy-fifth percentiles were used to represent the variation of data.  Chi-squared 119 
analysis was used for categorical data.  All data analysis was done using SPSS 16.0 120 
(Chicago, IL).   121 
Results 122 
Female gender (p = 0.04), body mass index (p < 0.001), knee replacement (p < 0.001), 123 
increasing age (p < 0.001), and an increase in age-adjusted Charlson Index (p < 0.0001) 124 
were risk factors for developing PE (Table 2).  Type of arthroplasty (revision versus 125 
primary) did not predict development of PE.  There were no differences between the 126 
confirmed PE positive and confirmed PE negative groups with regards to proportion of 127 
patients with an INR greater than two on the day of or prior to the work-up (9.2% in PE 128 
positive versus 7.9% in PE negative; p = 0.55).  On the first day after the scan, the PE 129 
negative group tended to have a higher percentage of patients (p = 0.11) with an INR 130 
greater than two.  On post-scan days three, four, and five, there was a higher percentage 131 
(p = 0.009, 0.0001, and 0.0002, respectively) of PE positive patients with an INR greater 132 
than two (Fig.3).  Patients with confirmed PE had higher INR on POD five (p = 0.02) 133 
compared to confirmed PE negative.  When aggregating confirmed PE negative patients 134 
with patients that were not worked-up, PE positive patients had a higher INR on POD 135 
two, three, four, and five (p = 0.012, p = 0.001, p < 0.001, and p < 0.001, respectively).   136 
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Discussion 137 
Pulmonary embolism is a dreaded and life-threatening complication that can develop 138 
after TJA, with an incidence of 1.1 to 1.82% following TKA and 0.51 to 0.9% after THA 139 
[12,18,19].  The 2008 updated ACCP guidelines regarding postoperative PE prophylaxis 140 
in musculoskeletal patients [10], endorsed the use of LMWH, fondaparinux, or Vitamin-141 
K antagonists to achieve an INR between two and three.  These guidelines, however, 142 
assume that DVT is a proxy for PE. Even more, the ACCP guidelines do not consider the 143 
risk of severe bleeding associated with anticoagulation, which ranges from 5.0% to 5.6% 144 
following TKA and 0.6% to 1.6% after THA [8,9,17], as well as the risk for minor 145 
bleeding complications following TKA and THA (21% to 28% and 4.6% to 13.5%, 146 
respectively).  Safety and low risk of complications with the use of low-dose warfarin 147 
(i.e. aiming for an INR less than two) for preventing PE has been demonstrated [1].  We 148 
therefore asked whether an INR level greater than two, as dictated by the ACCP 149 
guidelines, following TJA is protective against PE.   150 
This study is limited by a number of issues.  First, while the relatively large size of 151 
patients undergoing evaluation for PE adds to its strength, some patients in this study 152 
may have received work-up for PE following discharge from the hospital that were not 153 
disclosed to their treating surgeon.  Second, due to the fact that our observational window 154 
was focused on in-hospital data only; incidence of PE may be skewed, and PE occurring 155 
up to three or more months post-operatively were not captured.  Third, due to the 156 
retrospective nature of the study, it is not possible to provide an accurate number 157 
(although small) of those patients that deviated from the main anticoagulation protocol 158 
(i.e. patients with previous PE, polycythemia vera, and those in a hypercoagulable state) 159 
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who received an alternate anticoagulation protocol.  Fourth, there are no set standards in 160 
defining PE and it is plausible that some of the emboli seen on lung scans (MDCT) were 161 
fat emboli that could not be distinguished from venous emboli.  Fifth, not all patients in 162 
this study had pulmonary angiography, which is considered the gold standard for 163 
diagnosis of PE.  Due to the invasive nature of the test and the costs involved, pulmonary 164 
angiography is reserved for only a limited number of patients.  Furthermore, not all 165 
patients included in this analysis underwent work-up for PE.  This led us to separate the 166 
cohort into three groups (PE positive, PE negative and not scanned).  While we make the 167 
assumption that asymptomatic patients were PE negative, this cannot be truly confirmed 168 
without invasive work-up. Sixth, this study is only evaluating the efficacy of an INR 169 
target (less than two) set at our institution.  These results do not exclude the possibility 170 
that a lower INR target would be as efficacious at preventing PE.   171 
This study highlights some important findings.  First, the incidence of PE is low (1.6%) 172 
and comparable to literature [14,19] using low-dose warfarin, with no fatal PE during the 173 
period of this study.  Second, there is no correlation between the level of INR and the 174 
development of PE.  It appears that PE could develop in any patient, including those with 175 
an INR greater than two.  These findings raise the possibility that either INR fails to 176 
measure the efficacy of warfarin as an anticoagulant or that prophylactic anticoagulation 177 
has no effect on the incidence of PE.  A study, (130,000 patients), demonstrated that the 178 
incidence of PE among patients without anticoagulation prophylaxis (0.12%) is the same 179 
as those receiving it (0.095%) [13].  Although, there is a division among the orthopaedic 180 
surgeons regarding the most effective modality, they agree that some form of VTE 181 
prophylaxis is warranted.  Some believe that improvements in surgical and anesthesia 182 
10 
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care for patients undergoing TJA have made administration of chemical anticoagulation 183 
unnecessary [2].   184 
Orthopaedic surgeons consistently take an active role in preventing PE; however, there 185 
are key differences between the manner that they and medical physicians approach this 186 
complication.  First, they observe that 8.9% to 25.6% of TJA patients develop DVT, 187 
while only 0.5% to 2.0% developed PE [14,19].  For this reason, the American 188 
Association of Orthopaedic Surgeons (AAOS) recommends treating DVT and PE as 189 
separate entities.  Second, they are committed to minimizing bleeding complications in 190 
their surgical patients; these can be as devastating to patients as PE [15].  A study 191 
comparing low-dose warfarin with a target INR of 1.5 to two with a historical control 192 
group with a target INR of two to three, found no difference in the incidence of DVT, PE, 193 
or death [4,7].  Expectedly though, a higher incidence of bleeding complications occurs 194 
in the higher target INR group.  Major bleeding complications can be a foundation for 195 
infection, wound healing problems, functional disability, and prosthetic loosening [7].  196 
All of these consequences can lead to reoperation and increase in morbidity and 197 
mortality.  Third, pneumatic compression boots and aspirin, along with regional 198 
anesthesia, are suggested as being non-inferior to chemoprophylactic anticoagulants at 199 
preventing PE without the increased bleeding complications [6].  Interestingly, potent 200 
anticoagulants like warfarin and LMWH are associated with increased all-cause mortality 201 
rates, including PE, when compared to pneumatic compression boots and aspirin [20].  It 202 
is from this point of view that the AAOS created the guidelines stating that patients at a 203 
standard risk of both PE and bleeding can be given aspirin, LMWH, synthetic 204 
pentasaccharides, or warfarin to reach an INR goal of less than or equal to two [11].  A 205 
11 
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previous prospective study from this institution that involved performing preoperative 206 
and postoperative VQ scans in a consecutive series of patients undergoing TJA found that 207 
low dose warfarin (with an INR goal of less than two) is effective at minimizing 208 
development of PE, with a low (2.4%) bleeding complication [1].  Based on these 209 
findings, we have used low-dose warfarin as a prophylaxis for prevention of PE in our 210 
patients over the last two decades.   211 
The most pertinent finding of this study is that an INR greater than two does not appear 212 
to protect against PE.  Thus, implementing the recommendations of ACCP [10] in aiming 213 
for an INR greater than two may not protect these patients against PE, while exposing 214 
them to the undue risk of bleeding and all untoward consequences that may ensue [8,9].  215 
Despite the limitations, we believe our data and that in the literature casts doubt on the 216 
belief that administration of aggressive anticoagulation can and does protect patients 217 
against development of PE. 218 
12 
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Legends 
 
Fig. 1 Graph shows median INR versus day of surgery (columns, left axis) and 
histogram displaying PE work-up day of scan relative to POD (area curve; right axis).  
POD two was the maximum day of scans for both positive and negative PE patients.   
Fig. 2 Graph shows percentage of patients with INR greater than two from preoperative 
to POD five.   
Fig. 3 Graph shows percentage of patients with INR greater than two by day of scan 
(lines; right axis), as well as median INR related to the day of scan (columns; left axis).  
Day of scan is 0, the five days before the scan is in reverse chronological order as -1 
through -5, and the five days after the scan is days 1 through 5. Displays median values 
between positive PE and negative PE patients.  On the day of scan, there was no 
difference (p = 0.63) between INR values.  PE positive patients had higher INR values on 
post-scan days three, four, and five (p = 0.009, p < 0.001, and p < 0.001, respectively). 
 
